Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 24, 2025
Plasma Alzheimer's disease biomarker relationships with incident abnormal amyloid PETPetrice M Cogswell, Heather J Wiste, Stephen D Weigand, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 30, 2025
Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer's disease biomarker measurement: Results and consensus of the Global Biomarker Standardization ConsortiumInge M W Verberk, Mariam Gouda, Daniel Antwi-Berko, et al.
Annals of Neurology|July 4, 2024
Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis PatientsMatthew R Brier, Suzanne E Schindler, Amber Salter, et al.
Science Translational Medicine|April 21, 2017
Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathyKiran Yanamandra, Tirth K Patel, Hong Jiang, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 16, 2024
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aβ42/40 ratio to identify presence of brain amyloidMatthew R Meyer, Kristopher M Kirmess, Stephanie Eastwood, et al.
Brain : a Journal of Neurology|February 25, 2026
Modelling the temporal evolution of plasma p-tau217, amyloid PET, tau PET and cognitionPetrice M Cogswell, Emily S Lundt, Terry M Therneau, et al.
Nature Medicine|April 9, 2025
Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platformSebastian Palmqvist, Noëlle Warmenhoven, Federica Anastasi, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 30, 2025
Association of plasma Alzheimer's disease biomarkers with cognitive decline in cognitively unimpaired individualsPetrice M Cogswell, Heather J Wiste, Terry M Therneau, et al.
Pageof 6